Patents by Inventor Jotham W. Coe
Jotham W. Coe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230382901Abstract: Disclosed are heteroaryl amide inhibitors of CD38 and methods of making and using the same in disease and disorder treatment.Type: ApplicationFiled: October 8, 2021Publication date: November 30, 2023Inventors: Robert A. VOLKMANN, Jotham W. COE, Eric VERDIN, Rosalba PERRONE, Margaret JACKSON, Frederick R. NELSON, Elena SILVA, Steve FELSTEAD
-
Patent number: 7456177Abstract: The present invention provides a compound having the structure of formula I: wherein R1 is hydrogen, (C1–C6) alkyl, unconjugated (C3–C6) alkenyl, benzyl, YC(?O)(C1–C6) alkyl or —CH2CH2—O—(C1–C4) alkyl; X is CH2 or CH2CH2; Y is (C2–C6) alkylene; Z is (CH2)m, CF2, or C(?O), where m is 0, 1 or 2; R2 and R3 are selected independently from hydrogen, halogen, —(C1–C6) alkyl optionally substituted with from 1 to 7 halogen atoms, and —O(C1–C6) alkyl optionally substituted with from 1 to 7 halogen atoms, or R2 and R3 each together with the atom to which it is connected independently form C(?O), S?O, S(?O)2, or N?O; and is a 5- to 7-membered monocyclic heteroaryl group selected from pyridinyl, pyridone, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, cinnolinyl, triazinyl, oxadiazolyl, thiadiazolyl and furazanyl groups.Type: GrantFiled: July 12, 2004Date of Patent: November 25, 2008Assignee: Pfizer Inc.Inventors: Martin P. Allen, Jotham W. Coe, Spiros Liras, Christopher J. O'Donnell, Brian T. O'Neill
-
Patent number: 7442694Abstract: The present invention relates to a compounds of formula I: wherein A, B, D, E and F are defined herein; that are useful in treating central nervous system (CNS) diseases, disorders and conditions, such as but not limited to nicotine addiction, schizophrenia, depression, Alzheimer's disease, Parkinson's disease and ADHD. The present invention further comprises pharmaceutical compositions containing such compounds and methods of treatment comprising the use of such compounds.Type: GrantFiled: September 8, 2003Date of Patent: October 28, 2008Assignee: Pfizer IncInventors: Jotham W. Coe, Christopher J. O'Donnell, Brian T. O'Neill, Lawrence A. Vincent
-
Patent number: 7241887Abstract: The subject invention relates to 3-azabicyclo[3.2.1]octane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid receptors. The subject invention also particularly relates to using such derivatives to treat certain disorders and conditions, for example irritable bowel syndrome, drug addiction, depression, anxiety, schizophrenia and eating disorders, among others.Type: GrantFiled: April 14, 2004Date of Patent: July 10, 2007Assignee: Pfizer IncInventors: Jotham W. Coe, Stanton McHardy, Crystal G. Bashore
-
Patent number: 7056930Abstract: The subject invention relates to 2-azabicyclo[3.3.1]nonane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid receptors. The subject invention also particularly relates to using such derivatives to treat certain disorders and conditions, for example irritable bowel syndrome, drug addiction, including alcohol addiction, depression, anxiety, schizophrenia and eating disorders, among others, as are more fully described herein.Type: GrantFiled: January 22, 2004Date of Patent: June 6, 2006Assignee: Pfizer Inc.Inventors: Jotham W. Coe, Stanton McHardy
-
Publication number: 20040259859Abstract: The subject invention relates to 3-azabicyclo[3.2.1]octane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid receptors. The subject invention also particularly relates to using such derivatives to treat certain disorders and conditions, for example irritable bowel syndrome, drug addiction, depression, anxiety, schizophrenia and eating disorders, among others.Type: ApplicationFiled: April 14, 2004Publication date: December 23, 2004Applicant: Pfizer IncInventors: Jotham W. Coe, Stanton McHardy, Crystal G. Bashore
-
Publication number: 20040224963Abstract: Pharmaceutical compositions are disclosed for the treatment of nicotine dependence or addiction, tobacco dependence or addiction, reduction of nicotine withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse or other behavioral dependencies. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.Type: ApplicationFiled: March 4, 2004Publication date: November 11, 2004Applicant: Pfizer IncInventors: Jotham W. Coe, Philip A. Iredale, Steven B. Sands
-
Publication number: 20040224962Abstract: Pharmaceutical compositions are disclosed for the treatment of obesity, an overweight condition and compulsive overeating. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.Type: ApplicationFiled: March 3, 2004Publication date: November 11, 2004Applicant: Pfizer IncInventors: Jotham W. Coe, Philip A. Iredale, Steven B. Sands
-
Publication number: 20040204453Abstract: The subject invention relates to 4-phenyl-piperidine derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by an opioid receptor. The subject also particularly relates to using such derivatives to treat certain disease states, disorders and conditions, for example irritable bowel syndrome, drug addiction or dependency, including alcohol addiction, depression, anxiety, schizophrenia, anxiety, schizophrenia and eating disorders, among numerous other disease states, disorders and conditions as more fully described herein.Type: ApplicationFiled: January 22, 2004Publication date: October 14, 2004Applicant: Pfizer IncInventors: Stanton McHardy, Spiros Liras, Sara Guediche, Jotham W. Coe
-
Publication number: 20040204445Abstract: The subject invention relates to 2-azabicyclo[3.3.1]nonane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid receptors. The subject invention also particularly relates to using such derivatives to treat certain disorders and conditions, for example irritable bowel syndrome, drug addiction, including alcohol addiction, depression, anxiety, schizophrenia and eating disorders, among others, as are more fully described herein.Type: ApplicationFiled: January 22, 2004Publication date: October 14, 2004Applicant: Pfizer Inc.Inventors: Jotham W. Coe, Stanton McHardy
-
Publication number: 20040167200Abstract: A pharmaceutical composition and method of modulating cholinergic function in a mammal comprising administration of a NRPA compound or a pharmaceutically acceptable salt thereof; and an anti-emetic/anti-nausea agent or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.Type: ApplicationFiled: February 20, 2004Publication date: August 26, 2004Applicant: Pfizer Inc.Inventors: Jotham W. Coe, Steven B. Sands
-
Publication number: 20040106603Abstract: The present invention relates to a compounds of formula I: 1Type: ApplicationFiled: September 8, 2003Publication date: June 3, 2004Applicant: Pfizer IncInventors: Jotham W. Coe, Christopher J. O'Donnell, Brian T. O'Neill, Lawrence A. Vincent
-
Publication number: 20030133951Abstract: Pharmaceutical compositions are disclosed for the treatment of acute, chronic and/or neuropathic pain. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anti-convulsants, anti-hypertensives, anti-arrythmics, antihistamines, steroids, caffeine, and botulinum toxin. The method of using these compounds and a method of treating acute, chronic and/or neuropathic pain and migraine in a mammal including a human is also disclosed.Type: ApplicationFiled: January 21, 2003Publication date: July 17, 2003Applicant: Pfizer Inc.Inventors: Jotham W. Coe, Steven B. Sands, Edmund P. Harrigan, Brian T. O'Neill, Eric J. Watsky
-
Publication number: 20030109544Abstract: Pharmaceutical compositions are disclosed for the treatment of nicotine dependence or addiction, tobacco dependence or addiction, reduction of nicotine withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-depressant or anxiolytic agent and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.Type: ApplicationFiled: January 21, 2003Publication date: June 12, 2003Applicant: Pfizer Inc.Inventors: Edmund P. Harrigan, Jotham W. Coe, Brian T. O'Neill, Steven B. Sands, Eric Jacob Watsky
-
Publication number: 20030008892Abstract: A pharmaceutical composition and method of modulating cholinergic function in a mammal comprising administration of a NRPA compound or a pharmaceutically acceptable salt thereof; and an anti-emetic/anti-nausea agent or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 25, 2002Publication date: January 9, 2003Applicant: Pfizer Inc.Inventors: Jotham W. Coe, Steven B. Sands
-
Publication number: 20010036943Abstract: Pharmaceutical compositions are disclosed for the treatment of acute, chronic and/or neuropathic pain. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors , tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anti-convulsants, anti-hypertensives, anti-arrythmics, antihistamines, steroids, caffeine, and botulinum toxin. The method of using these compounds and a method of treating acute, chronic and/or neuropathic pain and migraine in a mammal including a human is also disclosed.Type: ApplicationFiled: December 18, 2000Publication date: November 1, 2001Inventors: Jotham W. Coe, Steven B. Sands, Edmund P. Harrigan, Brian T. O'Neill, Eric J. Watsky
-
Patent number: 6080058Abstract: An apparatus for directing the flow of air in a laboratory-type hood. A laboratory hood is provided with a closure sash and the lower edge of the closure sash has an airfoil that extends into the laboratory hood work space.Type: GrantFiled: June 16, 1998Date of Patent: June 27, 2000Assignee: Pfizer Inc.Inventors: Jotham W. Coe, Daniel P. Brannegan
-
Patent number: 5583137Abstract: 2,6-Diaminopurines, 3,5-diamino-6,7,8,9-tetrahydrobenzo[b]thiophene[2,3-d]pyrimidines and 2,4-diaminothieno[3,2-d]pyrimidines useful as inhibitors of P-glycoproteins and potentiators of chemotherapeutic agents.Type: GrantFiled: August 17, 1994Date of Patent: December 10, 1996Assignee: Pfizer Inc.Inventors: Jotham W. Coe, Anton F. J. Fliri, Takushi Kaneko, Eric R. Larson
-
Patent number: 5536722Abstract: 2,4,6-Triaminotriazine derivatives as potentiators of chemotherapeutic agents in the treatment of cancer.Type: GrantFiled: May 11, 1994Date of Patent: July 16, 1996Assignee: Pfizer Inc.Inventors: Jotham W. Coe, Anton F. J. Fliri, Takushi Kaneko, Eric R. Larson
-
Patent number: RE40838Abstract: The subject invention relates to 2-azabicyclo[3.3.1]nonane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid receptors. The subject invention also particularly relates to using such derivatives to treat certain disorders and conditions, for example irritable bowel syndrome, drug addiction, including alcohol addiction, depression, anxiety, schizophrenia and eating disorders, among others, as are more fully described herein.Type: GrantFiled: October 18, 2007Date of Patent: July 7, 2009Assignee: Pfizer Inc.Inventors: Jotham W. Coe, Stanton F. McHardy